JP7434185B2 - 三置換ベンゾトリアゾール誘導体の使用方法 - Google Patents

三置換ベンゾトリアゾール誘導体の使用方法 Download PDF

Info

Publication number
JP7434185B2
JP7434185B2 JP2020566525A JP2020566525A JP7434185B2 JP 7434185 B2 JP7434185 B2 JP 7434185B2 JP 2020566525 A JP2020566525 A JP 2020566525A JP 2020566525 A JP2020566525 A JP 2020566525A JP 7434185 B2 JP7434185 B2 JP 7434185B2
Authority
JP
Japan
Prior art keywords
cancer
compound
item
cell lymphoma
lymphoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020566525A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021514395A5 (https=
JP2021514395A (ja
Inventor
ダニエル ウラネット，
ソン ウン チェ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Les Laboratoires Servier SAS
Original Assignee
Les Laboratoires Servier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Servier SAS filed Critical Les Laboratoires Servier SAS
Publication of JP2021514395A publication Critical patent/JP2021514395A/ja
Publication of JP2021514395A5 publication Critical patent/JP2021514395A5/ja
Priority to JP2023087801A priority Critical patent/JP2023109974A/ja
Application granted granted Critical
Publication of JP7434185B2 publication Critical patent/JP7434185B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020566525A 2018-02-20 2019-02-19 三置換ベンゾトリアゾール誘導体の使用方法 Active JP7434185B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023087801A JP2023109974A (ja) 2018-02-20 2023-05-29 三置換ベンゾトリアゾール誘導体の使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2018018679 2018-02-20
USPCT/US2018/018679 2018-02-20
PCT/US2019/018472 WO2019164794A1 (en) 2018-02-20 2019-02-19 Methods of use for trisubstituted benzotriazole derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023087801A Division JP2023109974A (ja) 2018-02-20 2023-05-29 三置換ベンゾトリアゾール誘導体の使用方法

Publications (3)

Publication Number Publication Date
JP2021514395A JP2021514395A (ja) 2021-06-10
JP2021514395A5 JP2021514395A5 (https=) 2022-03-01
JP7434185B2 true JP7434185B2 (ja) 2024-02-20

Family

ID=61692059

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020566525A Active JP7434185B2 (ja) 2018-02-20 2019-02-19 三置換ベンゾトリアゾール誘導体の使用方法
JP2023087801A Pending JP2023109974A (ja) 2018-02-20 2023-05-29 三置換ベンゾトリアゾール誘導体の使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023087801A Pending JP2023109974A (ja) 2018-02-20 2023-05-29 三置換ベンゾトリアゾール誘導体の使用方法

Country Status (13)

Country Link
US (2) US11717512B2 (https=)
EP (1) EP3755324B1 (https=)
JP (2) JP7434185B2 (https=)
KR (1) KR102861339B1 (https=)
CN (1) CN111757731B (https=)
AU (1) AU2019223906B2 (https=)
BR (1) BR112020016929A8 (https=)
CA (1) CA3091792A1 (https=)
ES (1) ES3038736T3 (https=)
MA (1) MA51897A (https=)
MX (1) MX2020008678A (https=)
TW (1) TWI818954B (https=)
WO (1) WO2019164794A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180369206A1 (en) 2017-04-24 2018-12-27 Aurigene Discovery Technologies Limited Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors
HRP20211462T1 (hr) 2017-04-24 2021-12-24 Aurigene Discovery Technologies Limited Postupci uporabe za trisupstituirane derivate benzotriazola kao inhibitora dihidroorotatne oksigenaze
TWI818954B (zh) 2018-02-20 2023-10-21 法商施維雅藥廠 三取代之苯并三唑衍生物的使用方法
JOP20210147A1 (ar) 2018-12-21 2023-01-30 Les Laboratoires Servier Sas صور بلورية وملح من مركب عضوي وتركيبات صيدلانية منه
CN111662872A (zh) * 2020-05-06 2020-09-15 西南医科大学附属医院 一种急性t淋巴细胞白血病阿糖胞苷耐药细胞株构建方法
WO2021262874A1 (en) 2020-06-24 2021-12-30 Servier Pharmaceuticals , Llc Use of a dhodh inhibitor compound in combination cancer therapy
CA3184024A1 (en) 2020-06-24 2021-12-30 Les Laboratoires Servier Use of a dhodh inhibitor compound in combination cancer therapy
ES3063941T3 (en) * 2020-08-27 2026-04-21 Servier Lab Combinations of a dhodh inhibitor and r-chop therapy for the treatment of diffuse large b-cell lymphoma, mantle cell lymphoma and burkitt lymphoma

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170224663A1 (en) 2013-02-25 2017-08-10 Aurigene Discovery Technologies Limited Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors
WO2018197997A1 (en) 2017-04-24 2018-11-01 Aurigene Discovery Technologies Limited Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors
JP2020517654A (ja) 2017-04-24 2020-06-18 アウリジーン ディスカバリー テクノロジーズ リミテッド ジヒドロオロト酸オキシゲナーゼの阻害剤としての三置換ベンゾトリアゾール誘導体の使用方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9708620A (es) 1995-05-10 1998-02-28 Pfizer Combinacion de metotrexate y tenidap para el tratamiento de artritis reumatoide.
WO2001024785A2 (en) 1999-10-01 2001-04-12 Institute Of Molecular And Cell Biology Dihydroorotate dehydrogenase inhibitors for the treatment of viral-mediated diseases
US6841561B1 (en) 1999-10-01 2005-01-11 Institute Of Molecular And Cell Biology Dihydroorotate dehydrogenase inhibitors for the treatment of viral-mediated diseases
WO2003006424A1 (en) 2001-07-10 2003-01-23 4Sc Ag Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
US7652051B2 (en) * 2004-08-25 2010-01-26 Targegen, Inc. Heterocyclic compounds and methods of use
ATE474833T1 (de) * 2004-09-22 2010-08-15 Janssen Pharmaceutica Nv Inhibitoren der wechselwirkung zwischen mdm2 und p53
JP2007015952A (ja) 2005-07-06 2007-01-25 Shionogi & Co Ltd ナフタレン誘導体
DE102005049953A1 (de) 2005-10-19 2007-04-26 Sanofi-Aventis Deutschland Gmbh Carbamoylbenzotriazol-derivate als Inhibitoren von Lipasen und Phospholipasen
WO2008028860A1 (en) 2006-09-08 2008-03-13 F. Hoffmann-La Roche Ag Benzotriazole kinase modulators
WO2010081898A1 (en) 2009-01-19 2010-07-22 Neurosearch A/S Novel benzotriazole derivatives useful for the treatment of cns disorders
EP2230232A1 (en) 2009-03-13 2010-09-22 Almirall, S.A. Addition salts of tromethamine with azabiphenylaminobenzoic acid derivatives as DHODH inhibitors
EP2228367A1 (en) 2009-03-13 2010-09-15 Almirall, S.A. Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors
US9316632B2 (en) 2009-03-17 2016-04-19 Marshall University Research Corporation Methods of screening chemotherapeutic agents and treating cancer
MY159575A (en) 2009-04-02 2017-01-13 Merck Serono Sa Dihydroorotate dehydrogenase inhibitors
ES2642109T3 (es) 2009-12-09 2017-11-15 Agios Pharmaceuticals, Inc. Compuestos terapéuticamente activos para su uso en el tratamiento de cáncer caracterizados por tener una mutación de IDH
WO2011143160A2 (en) 2010-05-10 2011-11-17 The Johns Hopkins University Metabolic inhibitor against tumors having an idh mutation
US9012464B2 (en) 2010-11-25 2015-04-21 Ratiopharm Gmbh Salts and polymorphic forms of Afatinib
WO2013049112A1 (en) 2011-09-27 2013-04-04 Emory University Detection of biomarkers using magnetic resonance
CN103965133B (zh) 2013-01-31 2018-11-30 华东理工大学 一种具有dhodh抑制活性的含n、s杂环化合物及其制备和用途
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US11730716B2 (en) 2014-05-08 2023-08-22 Kiora Pharmaceuticals Gmbh Compounds for treating ophthalmic diseases and disorders
US11096934B2 (en) 2015-09-01 2021-08-24 The Broad Institute, Inc. Compounds and methods useful for treating or preventing hematological cancers
JP6961879B2 (ja) 2015-12-30 2021-11-05 レ ラボラトワール セルヴィエ ソシエテ・パール・アクシオンス・サンプリフィエ 変異体イソクエン酸デヒドロゲナーゼを包含する腫瘍の処置
JOP20190094A1 (ar) 2016-10-27 2019-04-25 Broad Inst Inc مركبات 1، 2، 4-تريازولون تحمل ثلاثة بدائل عند المواقع 2، 4، 5 مفيدة كمثبطات لديهيدروجيناز ثنائي هيدرو أوروتات (dhodh)
WO2018136009A1 (en) 2017-01-20 2018-07-26 Aslan Pharmaceuticals Pte Ltd Combination therapy
US11311548B2 (en) 2017-03-02 2022-04-26 Aslan Pharmaceuticals Pte. Ltd. Cancer therapy
WO2019012030A1 (en) 2017-07-13 2019-01-17 INSERM (Institut National de la Santé et de la Recherche Médicale) DHODH INHIBITOR AND CHK1 INHIBITOR FOR THE TREATMENT OF CANCER
TWI818954B (zh) 2018-02-20 2023-10-21 法商施維雅藥廠 三取代之苯并三唑衍生物的使用方法
JP7126556B2 (ja) 2018-09-28 2022-08-26 富士フイルム株式会社 シタラビンを含む抗腫瘍剤、シタラビンと併用される抗腫瘍効果増強剤、抗腫瘍用キット、およびシタラビンと併用される抗腫瘍剤
WO2020109625A1 (en) 2018-11-30 2020-06-04 Fondazione Centro San Raffaele Combined treatment of primary central nervous system lymphoma
JOP20210147A1 (ar) 2018-12-21 2023-01-30 Les Laboratoires Servier Sas صور بلورية وملح من مركب عضوي وتركيبات صيدلانية منه
US12582667B2 (en) 2019-09-27 2026-03-24 The Rockefeller University Compositions and methods to treat metastatic gastrointestinal cancer
CA3184024A1 (en) 2020-06-24 2021-12-30 Les Laboratoires Servier Use of a dhodh inhibitor compound in combination cancer therapy
WO2021262874A1 (en) 2020-06-24 2021-12-30 Servier Pharmaceuticals , Llc Use of a dhodh inhibitor compound in combination cancer therapy
ES3063941T3 (en) 2020-08-27 2026-04-21 Servier Lab Combinations of a dhodh inhibitor and r-chop therapy for the treatment of diffuse large b-cell lymphoma, mantle cell lymphoma and burkitt lymphoma

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170224663A1 (en) 2013-02-25 2017-08-10 Aurigene Discovery Technologies Limited Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors
WO2018197997A1 (en) 2017-04-24 2018-11-01 Aurigene Discovery Technologies Limited Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors
JP2020517654A (ja) 2017-04-24 2020-06-18 アウリジーン ディスカバリー テクノロジーズ リミテッド ジヒドロオロト酸オキシゲナーゼの阻害剤としての三置換ベンゾトリアゾール誘導体の使用方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Current Treatment Options in Oncology，2015年，Vol.16，Article 58
Translational Cancer Research，2017年，Vol.6, Suppl.1，S109-S111

Also Published As

Publication number Publication date
CA3091792A1 (en) 2019-08-29
MA51897A (fr) 2020-12-30
ES3038736T3 (en) 2025-10-14
BR112020016929A2 (pt) 2020-12-15
EP3755324B1 (en) 2025-07-30
JP2023109974A (ja) 2023-08-08
CN111757731B (zh) 2024-06-25
BR112020016929A8 (pt) 2022-06-28
TW201938543A (zh) 2019-10-01
KR102861339B1 (ko) 2025-09-19
EP3755324C0 (en) 2025-07-30
US12290508B2 (en) 2025-05-06
CN111757731A (zh) 2020-10-09
AU2019223906B2 (en) 2024-11-21
US20240148697A1 (en) 2024-05-09
US11717512B2 (en) 2023-08-08
WO2019164794A1 (en) 2019-08-29
EP3755324A1 (en) 2020-12-30
AU2019223906A1 (en) 2020-09-10
MX2020008678A (es) 2020-09-25
JP2021514395A (ja) 2021-06-10
US20210113531A1 (en) 2021-04-22
KR20200123137A (ko) 2020-10-28
TWI818954B (zh) 2023-10-21

Similar Documents

Publication Publication Date Title
JP7434185B2 (ja) 三置換ベンゾトリアゾール誘導体の使用方法
JP2024166290A (ja) 血液癌の併用療法
EA029072B1 (ru) Комбинированная терапия, включающая соединение дигидропиразинопиразина и антагонист рецептора андрогена для лечения рака простаты
JP2020520923A (ja) がんを処置するための方法
CA2912830A1 (en) Specific cancer treatment regimens with ganetespib
KR102127125B1 (ko) 면역체크포인트 억제제를 포함하는 항암용 조성물
RU2746705C2 (ru) Комбинация bcl-2 ингибитора и mcl-1 ингибитора, их применения и фармацевтические композиции
CN112121052B (zh) 丙烯酰基苯并氮杂䓬类化合物在制备防治血液肿瘤药物中的用途
TWI753178B (zh) Mcl-1抑制劑與血液癌症標準療法之組合，其用途及醫藥組合物
JP2021522342A (ja) 急性骨髄性白血病の再燃のリスクを低下させ、生存を延長するための方法及び組成物
RU2415670C2 (ru) Усиливающий агент для радиационной терапии, включающий производное пиридина в качестве активного ингредиента
HK40043674A (en) Benzotriazole derivative for use in treating double and triple hit diffuse large b cell lymphoma
HK40043674B (en) Benzotriazole derivative for use in treating double and triple hit diffuse large b cell lymphoma
KR102687556B1 (ko) 종양 전이를 억제하는 방법
CN117599041B (zh) 去氢雌马酚及其衍生物作为新型辐射防护剂和细胞保护剂的医药用途
KR102960038B1 (ko) 화학요법 불응성 암을 치료하기 위한 신규한 조합 방안
CN111050801B (zh) 用于治疗癌症的增加bcl2-相关的细胞死亡激动剂表达的药剂
KR20240164549A (ko) 암 치료를 위한 metap2 억제제를 포함하는 조합
KR20250105460A (ko) Kras 억제제 및 shp2 억제제를 포함하는 조합 요법
CN121059588A (zh) 一种抗肿瘤药物及其应用
CN121177494A (zh) Ipi549和bmn673联合在治疗白血病中的应用
CN101155782A (zh) 以吡啶衍生物为有效成分的放射线治疗增强剂
HK1118807B (en) Potentiator for radiation therapy comprising pyridine derivative as active ingredient
HK1229695A1 (en) Novel methods for treating cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220218

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220218

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20220329

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220329

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20221222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221228

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230327

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230529

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230529

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20231124

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240109

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240207

R150 Certificate of patent or registration of utility model

Ref document number: 7434185

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150